Objective: Blood pressure, urine albumin-to-creatinine ratio, and estimated glomerular filtration rate (GFR) are highly correlated conditions. The longitudinal effect of exposure to postmenopausal estrogen therapy on these traits studied together has not been reported.
M icroalbuminuria, hypertension (HTN), and kidney disease are closely related conditions. Microalbuminuria often precedes HTN 1 and kidney disease 2 and may be a marker of increased severity of disease. 3 HTN can worsen kidney disease, and kidney disease can also lead to HTN. 4 The presence of any of these conditions also increases the risk of cardiovascular disease (CVD) and mortality, 5 which may be further increased by the presence of more than one of these conditions. 6 Despite many previous observational studies suggesting that postmenopausal estrogen (PME) may have cardioprotective effects for postmenopausal women, 7 large randomized controlled studies from the Women's Health Initiative (WHI) 8, 9 and the Heart and Estrogen/Progestin Replacement Study 10 showed an increased risk of CVD and stroke in women taking PME. PME use in the United States has declined dramatically since 2002. 11 The long-term effects of PME on blood pressure (BP) and kidney disease are not well defined. Results of studies of estrogen's effects on BP have been mixed. 12 Long-term oral contraceptives are known to increase BP 13 ; smaller, short-term trials have reported a decline in BP, 14, 15 whereas clinical trials such as the WHI 8 and the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial 16 noted little effect of PME on BP.
The effect of PME on the kidney is uncertain. Prior studies are few and primarily small and of case-control design. 17, 18 One large population study from Alberta, Canada, reported that PME was associated with a decline in estimated glomerular filtration rate (eGFR) over a 2-year period. 19 Effects of PME on microalbuminuria, a marker of endothelial dysfunction, 20 have been evaluated in only a limited number of studies. 17, 18, 21, 22 Previous small, short clinical trials showed no effect of oral or transdermal estrogen on microalbuminuria, 23, 24 whereas large observational studies reported decreased microalbuminuria in PME users. 21, 22, 25 The present study evaluated the cross-sectional and longitudinal association of PME with BP, kidney function, and albuminuria, as continuous and categorical outcomes. This study started in 1992, when PME use was high, and continued to 2005, after the WHI results were known.
METHODS
The Rancho Bernardo Study was established in 1972; the details of the initial study have been described previously. 26, 27 Briefly, this cohort was based on a planned suburban devel-opment in southern California that was largely white and middle to upper middle class. Of the target population, 5,052 (82%) individuals were recruited by telephone, of which 54% were women. The research protocol for each clinic visit was approved by the institutional review board of the University of California, San Diego; all participants signed a written informed consent form.
Between 1992 and 1996, 1,082 (980%) surviving local women participated in a research clinic visit focused on diabetes. We excluded 31 women younger than 50 years with uncertain menopause status and 7 women who failed to answer a question about ever use of oral PME. The remaining 1,044 women form the basis of the cross-sectional part of this report, of which 31.6% had never taken PME, 23.5% had taken PME previously (mean, 7.9 y), and 44.9% were taking PME at the time (mean, 16.5 y of use), as noted in Table 1 . Age-adjusted P G 0.05 for current users compared with past PME users. At baseline, women were seen between 8 AM and 11 AM after an overnight fast. Information about known heart disease and angina pectoris, HTN, menopause, diabetes, lifestyle habits, and current and past estrogen use was obtained by a trained interviewer using standard Rancho Bernardo Study questions and the Rose questionnaire. 28 Women reported current (within the past 2 wk), past, or never use of estrogen; a nurse examined pills or prescriptions brought to the clinic for validation of reported current medications, providing validation of 92.4% of reported current PME use. More than 80% of PME taken was oral conjugated equine estrogens (CEE) 0.625 mg/day without a progestin. Women who reported previous use but not current use within the previous 2 weeks were classified as past users. Women who had never taken PME were classified as never users. Information about current cigarette smoking, alcohol consumption (number of drinks per day during the last 2 wk), and physical exercise was also obtained. Height and weight were measured using a calibrated stadiometer and balance-beam scale with participants wearing light clothing and no shoes. Systolic (SBP) and diastolic BP (DBP) were measured twice in seated participants after a 5-minute rest, using the HTN Detection and Follow-up Program protocol. 29 Baseline laboratory tests on morning fasting blood included glucose, lipids, and serum creatinine. A single, clean-catch, untimed morning urine sample (usually second void of the day) was obtained, frozen, and shipped to the National Institutes of Health laboratory (Phoenix, AZ) of Dr. Peter Bennett. Urine albumin was measured using the Behring Nephelometer BNA (Dade Behring GmbH, Marburg, Germany). The lower limit of detection of the assay was 6.8 mg/dL; values less than 6.8 mg/dL were assigned a value of 6.7 mg/dL. The interassay coefficient of variance was 4.5%. Urine creatinine was measured by the kinetic alkaline picrate method using the Ciba-Corning Express (Corning, Medfield, MA). Serum creatinine was measured using a variation of the Jaffe enzymatic method at a Smith Kline Beacham laboratory on a Hitachi 911 analyzer (Roche Diagnostics, Indianapolis, IN), with interassay and intraassay coefficients of variance of 4.0%. Glomerular filtration rate was estimated (eGFR) using the abbreviated Modification of Diet in Renal Disease (MDRD) equation. 30 Lipids were measured in a Lipid Research Clinic Laboratory certified by the Centers for Disease Control and Prevention. Total cholesterol and triglyceride levels were measured by enzymatic methods with an ABA-200 biochromatic analyzer (Abbott, Abbott Park, IL), high-density lipoprotein cholesterol was measured by precipitation according to Lipid Research Clinic protocol, and low-density lipoprotein cholesterol was calculated by means of the formula of Friedewald et al. 31 As a categorical variable, HTN was defined by a physician diagnosis, BP medication use, and/or measured SBP of 140 mm Hg or higher or DBP of 90 mm Hg or higher. Diabetes was defined by the 1997 American Diabetes Association criteria, 32 a fasting plasma glucose level of 126 mg/dL or greater (7 mmol/L), physician diagnosis, or use of diabetes-specific medication. Hypercholesterolemia was defined as a total cho-lesterol level of 200 mg/dL or greater or use of cholesterollowering medication. Alcohol consumption was defined as at least one alcoholic beverage per week. Obesity was defined as a body mass index (BMI) of 30 kg/m 2 or greater; overweight, as a BMI of 25 to 29.9 kg/m 2 ; and normal weight, as a BMI lower than 25 kg/m 2 . Chronic kidney disease (CKD) was defined as an eGFR by the abbreviated MDRD equation of e60 mL/minute per 1.73 m 2 . 33 Microalbuminuria was defined by sex-specific criteria as a urine albumin-to-creatinine ratio (ACR) of 25 mg/g or greater, which approximates an albumin excretion rate of 30 Kg/minute 34 as reported in other studies. 22 Macroalbuminuria was defined as 355 mg/g or greater. 34 Because only nine participants had macroalbuminuria, the two categories were combined into one albuminuria group (Q25 mg/g) for these analyses.
Between 2003 and 2005, approximately 10 years after the baseline visit, surviving participants were invited to a follow-up visit in our research clinic. Again, a nurse validated pills and prescriptions, including PME use. BP was measured, and urine and plasma samples were collected using the same protocols used previously. Urine albumin and creatinine were measured in the same National Institutes of Health laboratory as in the prior visit using the same techniques, but serum creatinine was measured in the commercial Quest Laboratory also using a modified Jaffe enzymatic method on an Olympus 5400 (Olympus Diagnostic Systems and Beckman Coulter, Brea, CA). There were 443 participants (60.4% of survivors) who returned and answered questions regarding previous and current PME use. The most common reason for nonresponse was death, recorded in 310 women; other nonrespondents had moved away or were too busy, too ill, or institutionalized.
All analyses were performed using SAS software (version 9.2; SAS, Cary, NC). Descriptive statistics are reported as mean T SD. Most measures were normally distributed; however, urine ACR was skewed, and natural log (ln) transformation was performed, with presentation of geometric means and geometric SDs as well as medians and interquartile ranges in tables. The t and W 2 tests were used to evaluate differences between cohorts. Analysis of covariance was performed (PROC GLM) for cross-sectional analyses of continuous outcomes and categorical outcomes by PME status. Logistic regression was used to define the odds ratios (ORs; 95% CI) of the categorical outcomes of HTN, CKD (eGFR e60 mL/min per 1.73 m 2 ), and albuminuria (ACR Q25 mg/g) by PME status. Multivariate models were adjusted for age, BMI category (obese, overweight, and normal weight), HTN, diabetes, hypercholesterolemia, and smoking status (ever or never). Linear mixed models with population mean specifications were used to assess the prospective association between PME use and body weight, BP, serum creatinine, eGFR, and ACR to accommodate the different time points between visits. 35, 36 Statistical tests were two tailed, with statistical significance defined as P G 0.05.
Statistical power was determined by PASS software (Kaysville, UT). In the cross-sectional analysis, with 1,000 participants and > = 0.05, we had greater than 95% power to detect a less than 5 mL/minute per 1.73 m 2 difference in eGFR by the MDRD equation, with an SD up to 30. Similarly, for the ln of ACR, we had greater than 95% power to detect a difference of less than 0.5, with an SD up to 1.8.
RESULTS

Cross-sectional
The initial 1992-1996 visit included 1,044 women, who were the basis for the cross-sectional analyses. Their mean age was 71.9 T 10.8 years (range, 50-97 y), mean age at menopause was 47.2 T 6.5 years, and mean BMI was 24.7 T 4.2 kg/m 2 (range, 15.5-47.7 kg/m 2 ). Of the participants, 54.7% met the criteria for HTN and 5.4% had diabetes by American Diabetes Association criteria (fasting glucose level Q126 mg/dL, a physician's diagnosis, or the use of glucose-lowering medications). Overall, 330 (31.6%) participants had never used PME (never users), 245 (23.5%) reported PME use in the past (past users), and 469 (44.9%) were current PME users (current users). Albuminuria was present in 19.8% (G1% met criteria for macroalbuminuria, n = 9), and CKD based on GFR was present in 37.6%. Table 1 shows the baseline characteristics of the cohort by PME status in age-adjusted and multivariate-adjusted models. Current users were younger than both past and never users (P G 0.001) and had been taking PME for an average of 16.5 years compared with the past users, who reported PME for an average of 7.9 years (age-adjusted P G 0.001). Current users were also more likely to have had a hysterectomy (61.8%; age-adjusted P G 0.001), whereas never users were the least likely to have had a hysterectomy (29.1%).
BMI was lowest in current users, intermediate in past users, and greatest in never users (age-adjusted P = 0.04), but the women as a whole had a mean BMI of only 24.8 kg/m 2 . Serum creatinine was lowest in the current PME users (ageadjusted P = 0.01, multivariate-adjusted P = 0.02). eGFR based on the MDRD equation was lower in never users when compared with either current or past users, as shown in Table 1 and Figure 1 (unadjusted P G 0.0001, multivariateadjusted P = 0.03). There was no difference in ACR by PME status. DBP was highest in never users (age-adjusted P = 0.07, multivariate-adjusted P = 0.01), but SBP did not differ by PME status after adjustment for covariates.
Also shown in Table 1 , both diabetes (age-adjusted P G 0.01) and CKD (eGFR G60 mL/min per 1.73 m 2 ) were most common in never users (age-adjusted P = 0.02). HTN was less common in the current users compared with either the never users (ageadjusted P = 0.04) or the past users (age-adjusted P G 0.05).
FIG. 1. Differences in eGFR by oral PME use at baseline visit (1992) (1993) (1994) (1995) (1996) . Both current and past users of PME had greater eGFR (as determined by the abbreviated MDRD equation) than did the never users (unadjusted P G 0.0001 and P = 0.038, respectively). Results were unchanged after age and multivariate adjustments. eGFR, estimated glomerular filtration rate; PME, postmenopausal estrogen; MDRD, Modification of Diet and Renal Disease. , diabetes (Y/N), ever smoker (Y/N), hypercholesterolemia (total cholesterol Q200 mg/dL or taking cholesterol-lowering medication; Y/N), HTN (as noted previously; Y/N, not entered for HTN model). OR, odds ratio; CKD, chronic kidney disease; HTN, hypertension; PME, postmenopausal estrogen; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate. Table 2 indicates the crude, age-adjusted, and multivariateadjusted ORs between the PME use groups and the presence of the categorical traits CKD, albuminuria, and HTN. After adjustment for the covariates listed, current users had lower odds of CKD (OR, 0.66; 95% CI, 0.48-0.90) compared with never users but did not differ for BP or ACR.
Prospective
The 443 participants in the prospective study (60.4% of surviving participants) who returned for a follow-up visit after a mean of 10.1 T 0.9 years included 87 women who were never users of PME, 247 women who were past users, and 109 women who were current users; 99 of the 109 current users (90.8%) had used PME continuously between the baseline and follow-up visits, which was validated by pill or prescription examination at both visits. Women who attended the follow-up visit differed from those who did not; at baseline, they were younger (65.4 T 9.0 vs 76.6 T 9.5 y; P G 0.0001) and had lower serum creatinine levels (0.90 T 0.2 vs 0.96 T 0.2 mg/dL; P = 0.02), higher BMI (25.1 3) Data are presented as mean T SD, unless otherwise noted. Overall P values were determined by linear mixed models. Multivariate adjustment includes age, weight (obese, overweight, normal BMI), diabetes (Y/N), ever smoker (Y/N), hypercholesterolemia (total cholesterol Q200 mg/dL or taking cholesterol-lowering medication; Y/N), HTN (as noted previously; Y/N, not entered for HTN model). Bold P value signifies P G 0.05. PME, postmenopausal estrogen; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; UACR, urine albumin-to-creatinine ratio (natural log due to nonnormal distribution); HTN, hypertension. after age adjustment. Women in the follow-up cohort were more likely to be current users of PME at baseline (50.9% vs 34.6% of past users followed up and 36.1% of never users; P G 0.001), but this association was not statistically significant after adjustment for baseline age (P = 0.83).
As shown in Table 3 , after a mean of 10.1 T 0.9 years of follow-up, eGFR declined over time in each of the three PME use groups by a mean of 5.9 T 14.9 mL/minute per 1.73 m 2 over 10.1 years, which is a mean yearly decline of 0.57 T 1.5 mL/minute per 1.73 m 2 , and there was no difference by PME use ( Fig. 2A) . As shown in Figure 2B , ACR differed over time by PME use such that never users had an ageadjusted increase in their ACR over the 10-year follow-up period (ln 0.31 mg/g; P G 0.001).
BP also differed over time and between PME groups (as shown in Fig. 2C, D) such that SBP did not differ in the past and current user groups, but never users exhibited an ageadjusted increase in SBP over time (mean increase, 6 mm Hg;
FIG. 2. Changes in eGFR, UACR, and blood pressure by oral PME use over the È10-year follow-up period. A: eGFR (by the abbreviated MDRD equation). All of the participants had significant declines in their eGFR over the follow-up period (P G 0.001). There were no differences among the three groups at the baseline visit, the follow-up visit, or in their decline over time (P 9 0.05). B: UACR. Overall, there was a difference in ACR by PME use (age-adjusted P = 0.003). Never users had a significant increase in ACR (age-adjusted P = 0.0007), whereas current users had a significant decline over time (age-adjusted P = 0.02). For statistics performed on the natural log of ACR due to nonnormal distribution, geometric means are presented (in parentheses). C: SBP. At the baseline visit and the follow-up visit, no differences in SBP were noted by PME usage. Never users showed an increase in SBP over the follow-up (age-adjusted P = 0.02), whereas there was no change in the past and current users. Overall, by mixed-model analysis, the differences among the three PME groups were statistically significant (age-adjusted P = 0.05). D: DBP. At the baseline visit, DBP was similar in the three PME groups, but by the follow-up visit, never users had higher DBP than did the current and past users (age-adjusted P = 0.04), in part because the current and past users had significant declines in their DBP over the 10-year follow-up (age-adjusted P G 0.001 for each group). The overall mixed model among the three PME groups had age-adjusted P = 0.07. eGFR, estimated glomerular filtration rate; PME, postmenopausal estrogen; MDRD, Modification of Diet and Renal Disease; ACR, albumin-to-creatinine ratio; UACR, urine albumin-to-creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. P = 0.02). The multivariate-adjusted difference remained (P = 0.05). At follow-up, DBP was greatest in the never PME users (age-adjusted P = 0.04) when compared with past and current users. Over the follow-up period, the DBP of never users showed no significant age-adjusted change (P = 0.1), whereas past users (age-adjusted P G 0.0001) and current users (age-adjusted P G 0.0001) showed similar declines in their DBP (Fig. 2D) .
DISCUSSION
This study demonstrates some statistically significant associations between PME use and BP, eGFR, and albuminuria. Results differed in the cross-sectional and prospective studies. Cross-sectional analyses demonstrated (after adjustment for age, BMI, smoking, presence of diabetes, HTN, and hypercholesterolemia) that current users had lower BP and higher eGFR than did never and past users. As in prospective studies of older women, in which participation is reduced by death and illness, the prospective cohort was younger and healthier than the original cohort. Nevertheless, we found in the age-adjusted analyses that continuous long-term (È10 y) PME use was associated with decreased DBP and ACR over time. In the prospective cohort, 186 women (95% of current and never users) maintained the same estrogen use status over the entire follow-up period, which is, to our knowledge, the longest confirmed continuous follow-up period of PME use and measures of kidney function and albuminuria.
In both human 37 and animal 38 studies, estrogen has a known vasodilatory effect on vascular smooth muscle, mediated through increased bioavailability and synthesis of nitric oxide and cyclic guanine monophosphate, 38 and may reduce the breakdown of nitric oxide by superoxide free radicals. 39, 40 This enhances vascular oxidative stress and anti-inflammatory action resulting in vasoprotection and contributes to improvements in GFR and BP. 41 Animal studies have also indicated a protective role for estrogen against glomerulosclerosis and albuminuria. 42 BP is a major risk factor for stroke and CVD. Although PME did increase the risk of stroke, 43 studies of PME use and BP have shown mixed results. 12, 15, 16 Diverse research designs, including varying types of participants (normotensive 16, 44 or hypertensive 45 ) or estrogen administration (oral 16 or transdermal 44 or injectable 45 ), may contribute to inconsistent results, as well as the addition of different progestins. 46 Our women were primarily taking CEE identified as Premarin (985%), without a progestin. After 3 years in the randomized, placebo-controlled PEPI trial, 16 there was no effect of any hormone regimen (opposed or unopposed CEE) on SBP or DBP. The PEPI participants were relatively young (45-64 y). Our findings that never users of PME did not have a decline in DBP yet demonstrated an increase in SBP over time, compared with both current and past users, may reflect survivor bias. In addition, the decline in DBP may be a marker of aortic stiffness and widened pulse pressure, which is not desirable because it has been shown to be another CVD risk factor, 47 although our current and past PME users displayed a change of only È4 mm Hg in their DBP over the follow-up period.
Our study adds to the mixed findings of prior prospective studies of PME and kidney function over time. In congruence with our findings, a 5-year follow-up of 491 postmenopausal women in the Insulin Resistance Atherosclerotic Study also showed no effect of PME on GFR but a decline in proteinuria. 22 A cross-sectional analysis from the Nurses' Health Study found that microalbuminuria was decreased in postmenopausal women who had been using oral PME for at least 6 years 21 ; GFR was not evaluated. A large case-control study of more than 4,300 women revealed a higher creatinine clearance in postmenopausal women taking PME, but this analysis was not adjusted for covariates; in contrast with our study, an increased risk of microalbuminuria after age and multivariate adjustment was reported. 18 Our results also contrast with the largest observational prospective study of PME on renal function, in which Ahmed et al 19 reported on 5,845 postmenopausal women who were at least 66 years old. In this study, PME was associated with a loss of renal function in a dose-dependent fashion. They showed a greater mean decline in eGFR (1.57 mL/min per 1.73 m 2 over 2 y) than our study using the same MDRD eGFR estimating equation. However, their use of an administrative database did not allow adjustment for covariates, and albuminuria was not assessed in the study.
Two small interventional clinical trials have assessed the effects of PME on proteinuria in patients with diabetes, and a third studied healthy women. The first had only 16 participants with both HTN and diabetes and reported a decline in proteinuria but an increase in creatinine clearance after 14 weeks of treatment with PME. 17 The other two studies indicated no change in microalbuminuria after 6 months of treatment in patients with diabetes 25 or healthy postmenopausal women. 23 Our study included only a small number of participants with diabetes and we did not have the power to evaluate PME in this subset of women.
Albuminuria is associated with an increased risk of CVD and all-cause mortality, even in older adults. 48 Although albuminuria may indicate glomerular damage in the kidney, 2 systemically, it is also a marker of vascular and endothelial damage and is associated with inflammation 49 and the coagulation cascade. Reducing ACR, which is a marker of microvascular disease, with PME may have clinical significance. For example, in this Rancho Bernardo population, ACR has been associated with decreased cognitive function, 50 but whether decreasing ACR may have long-term beneficial effects in such microvascular disease needs further investigation.
The strengths of our study include the well-characterized community base, with all three outcomes measured using the same methodology, which was state-of-the-art at the time of the baseline visit. There was a high prevalence of PME use validated at both visits by examination of pills and prescriptions. Data were collected before 2002, before major changes in hormone use followed publicity about the increased CVD risks shown in the large Heart and Estrogen/Progestin Replacement Study and WHI trials. These women probably started their estrogen before general awareness of the endometrial cancer risk associated with unopposed estrogen, and many continued with this regimen thereafter because they did not want to have intermittent bleeding and continuous-combined estrogen and progestin regimens were not available. More recent studies have much lower prevalence of PME use, mostly in younger and symptomatic women. Because medications were confirmed with pill bottles at both visits and in-depth interviews were performed for major CVD risk factors, fully adjusted models could be determined. In the longitudinal analysis, all but 10 of the baseline current users of PME had taken PME continuously over the entire follow-up, and all of the never users had consistently not taken PME throughout the course of their study, limiting the recall bias associated with complex medication histories in older women. To our knowledge, this is the only longitudinal study of PME use on kidney function and albuminuria that has confirmed continuous use of PME for approximately 10 years.
Some study limitations should be noted. Because of social class and ethnic homogeneity, conclusions may not be generalizable to the general population, but this reduces the healthy, wealthy woman bias that often determines who is prescribed estrogen. 51 Furthermore, as noted, participant bias selects against the return of those who have severe HTN and renal disease after the baseline visit. This is an observational study, so associations, particularly in the cross-sectional portion of the study, may not be causal. Cross-sectional studies have a number of limitations, most importantly the inability to establish causality, and may be influenced by confounding relationships and variables not studied. The prospective portion of the study allows us to evaluate changes over time, although residual confounding may exist. For example, there may be residual confounding by environmental variables, particularly diet and sodium intake, that may affect BP, which were not evaluated here. Protein intake may also confound the relationship with ACR.
We have determined eGFR based on the abbreviated MDRD equation, 30 which is most accurate in persons with a GFR of 60 mL/minute per 1.73 m 2 or lower, tending to overestimate GFR in healthy persons. 52 The goal of our study was to compare changes over time and between groups, rather than determine the precise GFR for each participant. In addition, the use of different laboratories for serum creatinine measurements, despite use of similar assay techniques, may have biased our longitudinal results. The anticipated trends toward higher serum creatinine and lower eGFR over time and by age were intact. All of the samples at each visit were analyzed by the same laboratory.
CONCLUSIONS
We found that current PME users had lower BP and eGFR and decreased odds of having CKD. However, our longitudinal study of younger and probably healthier survivors over a 10-year follow-up period revealed an increase in ACR in never users of PME but no effect on eGFR. Thus, we provide evidence that long-term continuous oral PME use may be inversely associated with albuminuria but has no substantially positive or inverse association with eGFR. Differences were noted in BP trends over time, particularly in never users of PME, which should be confirmed in further longitudinal and clinical studies.
